Statistics

Total Visits

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)45

Select a period of time:

Number of views in the range

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)30

Views

Views
January 20251
February 20257
March 202515
April 20252
May 20251
June 20251
July 20253
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States7
Spain6
Germany1
Hong Kong1
 

Top cities views

Views
Narón5
Chicago1
Council Bluffs1
Hong Kong1
Los Angeles1
Miami1
Raleigh1